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Abstract: Guanine-rich DNA can form four-stranded structures called G-quadruplexes (G4s) that can
regulate many biological processes. Metal complexes have shown high affinity and selectivity toward
the quadruplex structure. Here, we report the comparison of a panel of platinum (II) complexes for
quadruplex DNA selective recognition by exploring the aromatic core around terpyridine derivatives.
Their affinity and selectivity towards G4 structures of various topologies have been evaluated
by FRET-melting (Fluorescence Resonance Energy Transfert-melting) and Fluorescent Intercalator
Displacement (FID) assays, the latter performed by using three different fluorescent probes (Thiazole
Orange (TO), TO-PRO-3, and PhenDV). Their ability to bind covalently to the c-myc G4 structure
in vitro and their cytotoxicity potential in two ovarian cancerous cell lines were established. Our
results show that the aromatic surface of the metallic ligands governs, in vitro, their affinity, their
selectivity for the G4 over the duplex structures, and platination efficiency. However, the structural
modifications do not allow significant discrimination among the different G4 topologies. Moreover,
all compounds were tested on ovarian cancer cell lines and normal cell lines and were all able to
overcome cisplatin resistance highlighting their interest as new anticancer drugs.
Keywords: terpyridine platinum complexes; G-quadruplex
1. Introduction
Among the clinically relevant anticancer drugs, cisplatin is the most frequently used
chemotherapeutic drug particularly employed for the treatment of testicular, ovarian, lung, head, and
neck cancers. However, undesirable side effects, as well as the emergence of intrinsic or acquired
resistances, currently limit its use and drive the design and development of more effective and less
toxic analogues [1–3]. One of the considered strategies is to induce different DNA lesions and to
target specific DNA structures as G-quadruplexes (G4) [4]. G4 consists in the stacking of G-quartets
formed by four guanines linked together by reverse-Hoogsteen hydrogen bonds involving their N7.
G4s arise from DNA (or RNA) sequences that contain at least four runs of guanines and are stabilized
by physiological concentrations of alkali metal cations. A large amount of data provides evidence
that such structures could form in cells and may play important roles in biology, such as genomic
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stability, replication, transcription, translation, and telomere maintenance [5,6]. Bioinformatics [7,8],
cellular imaging [9–13], as well as high throughput sequencings of genomic DNA or RNA [14–16]
have contributed to identifying G4 prevalence at specific key genomic sequences such as telomere and
promoter regions of oncogenes. So far, they have been identified as potential drug targets, especially in
cancer [17–19]. Consequently, a large number of G4 binders based on organic planar structures [20]
have been synthesized, including metal complexes [21–29]. As an example, RHPS4 was one of the first
proof-of-concept drugs for the application of G-quadruplex-binding DNA molecules in anticancer
therapies [30]. Among metal complexes, platinum complexes have been extensively studied (for
review see References [23,24]). Moreover, platinum (II) can also form coordinate bonds with DNA, and
very stable adducts may result [3]. Besides double-stranded DNA, numerous examples indicate that
G4 can be covalently coordinated in vitro by platinum complexes either on adenines (N1 or N7) located
within the loops or on the guanines (N7) belonging to external G-quartets that transiently open [31–36].
Moreover, some of them were shown to target telomeres in cellulo by inducing their uncapping [33],
loss [37], dysfunction [38], and platination [39] while other complexes were shown to target c-myc
oncogene [40,41]. Despite the large body of data, the mechanism of action and the determinants that
drive the in vitro and cellular target recognitions of G4-platinum complexes are not yet established.
Metal-terpyridine complexes were shown to have good affinity towards G4 structures, due to their
square planar and square-based pyramidal geometries [21,29,36]: it is assumed that the metal ion
increases the ability of the ligand to display pi–pi stacking interactions with the external G-tetrad and
can replace a metal cation involved in the G-tetrad stabilization. The family of terpyridine platinum
complexes offers the opportunity to analyze in detail a potential structure–activity relationship. Some
of them have already been shown to stabilize and metallate in vitro human telomeric and c-myc G4s
via selective platination of adenine residues on the loops [31,42,43]. An NMR structure of Pt-ttpy
complexed with a G4 originating from the promoter region of c-myc oncogene suggests that the
predominant interaction occurs through the stacking of Pt-ttpy to the outer G-quartet and drives the
platination of the adenine residue at the 5’-end overhanging region [42]. All these data suggest that
this ligand is well suited for both G4 recognition and metal coordination. In addition, it is important to
underline that Pt-ttpy has been shown to be able to modify the structure of telomeres of cancerous
cell lines by inducing their loss and direct metalation [37,39]. Moreover, one of its derivatives, Pt-ctpy,
exhibits promising radiosensitization properties in human glioblastoma and lung cancer cells [44].
In conclusion, the terpyridine platinum complexes are, therefore, promising compounds employed for
cancer treatment alone or in combination with radiation.
These encouraging properties prompted us to explore the aromatic core around the Pt-terpyridine
motif to raise new properties in terms of G4 affinity and selectivity for drug discovery in comparison
with Pt-ttpy that has already been evaluated on the human telomeric and c-myc G4s [29,31,36,43]. The
binding properties of these complexes towards G4s were studied with a panel of oligonucleotides
(G4 of various topologies and duplex DNA) using FRET-melting assay and Fluorescent Intercalator
Displacement (FID), the latter being performed in the presence of three different probes, namely
Thiazole Orange (TO) [45], TO-PRO-3 [46], and PhenDV [47], to determine the key elements for G4
affinity and selectivity. In parallel, platination selectivity and efficiency in competition conditions with
duplex DNA have been studied. At last, the potential of these Pt(II)-complexes as antitumor agents
has been evaluated by studying their effects on the growth of cisplatin-sensitive and cisplatin-resistant
cell lines.
2. Results
2.1. Panel of Platinum Complexes
Terpyridine (tpy) scaffold is a well-used metal ligand and has been extensively derivatized
by Vilar et al. to stabilize G4 [22] yet shows poor selectivity toward duplex DNA. To overcome
this selectivity issue, the extension of the aromatic surface of the Pt-complexes was successfully
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proposed. Both Pt-BisQ and Pt-ttpy, bearing respectively two quinoline moieties or a tolyl
group, display higher affinity and selectivity towards telomeric G4 by limiting duplex DNA
intercalation [29,31,36]. Our group synthesized Pt-ctpy, based on the Pt-ttpy scaffold, by adding
a short in situ protonable chain [29]. This chain increases the water solubility and the affinity towards
telomeric G4 by adding supplementary electrostatic interactions with the G4-DNA [48]. To assess a
structure–activity-relationship study, we extended our panel of platinum complexes (Scheme 1).
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A double Stille coupling of dichloropyrimidine 1 afforded compound 2 in very good yield.
Deprotection of the phenol group followed by O-alkylation allowed the formation of cpym. Compound
vpym, bearing a vinyl linker, was prepared as described in the literature [50]. Both vpym and cpym
ligands were platinated using PtCl2(DMSO)2. In addition, the aromatic surface of the complexes
has also been extended on the metal center by replacing the labile ligand (Cl−) on Pt-tpy by a
phenylacetylene group (Figure S1). This complex was obtained by transmetallation of the in situ
generated copper (I) phenylacetylide on the Pt-tpy. Pt(PA)-tPy does not contain any labile ligand and
consequently is not able to metallate the DNA bases anymore.
2.2. Interaction Measurements
Binding properties towards G4 structures of the synthesized complexes were evaluated by
performing biophysical assays, such as FRET-melting and G4-FID assays, in the presence of
several G4-forming oligonucleotides representative of different folding topologies: 22AG human
telomeric sequence (polymorphic), 21CTA human telomeric sequence variant (antiparallel), CEB25-WT
minisatellite sequence (parallel with a central long propeller loop), and c-myc protooncogene sequence
(parallel with short propeller loops).
The affinity and selectivity for G4-DNA of our panel of platinum complexes have been evaluated
by FRET-melting [51] and G4-FID assays [45].
The ligand-induced stabilization measured by FRET-melting experiments (∆Tm) is plotted for
all compounds in Figure 1A–E, and the benchmark compound PhenDC3 was used as the control
compound. Most importantly, Pt-BisQ, Pt-ctpy, and Pt-ttpy emerge as the best G4 stabilizers of the
series, with ∆Tm values ranging from 10 to 25 ◦C for all G4-DNA structures (Figure 1A and Table S1).
Pt-vpym, Pt-cpym, and Pt-tpy exhibit lower stabilizing capacities towards G4s while Pt(PA)-tpy shows
a complete lack of stabilization properties. Among the different topologies exhibiting a similar melting
temperature (around 60 ◦C), all complexes show similar stabilizing properties for 22AG, CEB25-WT,
and 21CTA, as compared to c-myc that tends to be less stabilized by the different complexes. In addition,
the selectivity of the compounds towards G4s vs. duplex DNA has been evaluated by carrying out
competition experiments in the presence of 10 equivalents of ds26 (Figure 1B–E): all complexes show
moderate selectivity since their ∆Tm is partially affected by the presence of ds26. One exception is
represented by Pt-vpym which has stabilizing properties towards 21CTA and c-myc that increased in
the presence of ds26 for a reason that is not yet elucidated but that is likely an artefact.
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Figure 1. (A) A radar plot representing ∆Tm values obtained from FRET-melting experiments in the
presence of various terpyridine-Pt complexes: Pt-ctpy, Pt-BisQ, Pt-ttpy, Pt-tpy, Pt-vpym, Pt-cpym,
and Pt(PA)-tpy and PhenDC3, used as a control. ∆Tm of (B) F-21-T, (C) F-CEB25-WT-T, (D) F-21CTA-T,
and (E) F-c-myc-T in the presence of 0 (black bars) or 10 µM (grey bars) of duplex DNA(ds26) used as
the competitor in a K+1 buffer, except for F-21-T (K+10 buffer). The values are given in Table S1.
Since all these complexes (except for Pt(PA)-tpy) are susceptible to induce platination reactions,
they can be exacerbated by a high temperature and by an increased number of nucleophilic sites which
are exposed during unfolding (increased N7 G free sites); we wonder if such a reaction could occur
during FRET-melting experi ents and to what extent. Therefore, we followed the extent of platination
reactions of c-myc and 22AG (same sequenc s as those used for FRET-melting but witho t fluorophore
labeling) as a f nction of the melting temperature using 32P-labelled oligonucleotides a d denaturing
gel electrophoresis (Figure 2). Pt-ttpy, Pt-tpy, and Pt-BisQ clearly platinate c-myc and 22AG (except
for Pt-BisQ) during melting temperature experiments and the extent of platination depends both on
the sequence (c-myc (60%) > 22AG (20%)) and on the complex (Pt-ttpy > Pt-tpy > Pt-BisQ). These
results suggest that these platination reactions may therefore bias the melting temperature value.
Pt-ctpy, Pt-vpym, and Pt-cpym do not give any defined platination product, and thus, they were not
evaluated in this melting temperature condition (see Section 2.3. Quadruplex Platination).
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Figure 2. The denaturing gel of the plati atio tions of (A) c-myc and (B) 22AG (0.2 µM) in the
presence of Pt-ttpy (square), Pt-tpy (triangle), and Pt-Bis (circle) (1 µ , 5 eq) and the quantification of
the platination products for (C) c-myc and (D) 22AG were conducted under FRET-melting conditions:
A temperature gradient of 25 ◦C for 5 min and then 0.5 ◦C/min up to 95 ◦C using K+1 and K+ 10
buffers, respectively. An example of the quantified platination products are highlighted in both (A)
and (B) by colored squares.
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Consequently, the relative binding ability of the complexes for the various G4s should be
determined in the conditions that are less favorable to platination reaction, the room temperature
and short incubation time: all these conditions are gathered in a G4-FID assay. A G4-FID assay
is generally performed in the presence of thiazole orange (TO) as an on–off fluorescent probe for
DNA structures [48]. TO-G4-FID allowed us to evaluate the binding properties for all the platinum
complexes (Figure 3A, Figure S2 and Table S2), except Pt-vpym which had spectral properties that are
incompatible with TO (Figure S3). The metallic complexes can be ranked in two groups: the first group,
including Pt-BisQ, Pt-ctpy, and Pt-ttpy, efficiently displaces TO from all the G4 (>80% displacement
at 1 µM) as compared to the duplex ds26 (<20% displacement) (Figures S2 and S4), whereas the second
group, including Pt-cpym, Pt-tpy, and Pt(PA)-tpy, displaces less efficiently TO (<60%). For all of them,
only a small displacement of the probe is observed in the presence of duplex ds26 (Figures S2 and S4).
As the binding constants of TO for all the tested G4s are in the same range (~106 M−1), we could assess
that none of the metal complexes has a clear preference for a G4 structure.
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Figure 3. The radar plot representing the percent of the probe displacement at 1 µM of the Pt(II)
complexs (Pt-ctpy, Pt-BisQ, Pt-ttpy, Pt-tpy, Pt-vpym, Pt-cpym, and Pt(PA)-tpy) and the PhenDC3
used as control for the G4-FID assay. The experiments are performed in the presence of 22AG, c-myc,
21CTA, and CEB25-WT with (A) Thiazole Orange (TO) (2 eq.), (B) TO-PRO-3 (2 eq.), or (C) Phen DV
(1.5 eq.) in K+100 buffer. The values are given in Tables S2–S4.
However, in order to evaluate Pt-vpym, we used the TO-PRO-3-G4-FID assay developed in our
group [48] to compare the entire panel of ligands. Of interest, TO and TO-PRO-3 exhibit similar affinity
constants towards all the tested G4s structures (Ka ~106 M−1) [48]. The TO-PRO-3-G4-FID assay shows
that Pt-vpym displays a moderate affinity for G4 structures (30% displacement) with poor selectivity
vs. duplex DNA (Figure 3B, Figures S2 and S4 and Table S3) in contrast to Pt-BisQ, Pt-ctpy, and
Pt-ttpy (>60% displacement). Of note, only a weak displacement for Pt-tpy, Pt-cpym, and Pt(PA)-tpy
has been observed.
In addition, we tested our complexes in a G4-FID assay using PhenDV which is an off–on probe
developed in our laboratory [47]. This probe improves the sensitivity of the G4-FID assay, as the read
out, different from the two previous reported FID assays, relies on increased fluorescence: PhenDV
Molecules 2019, 24, 404 7 of 19
fluorescence is strongly quenched when it is bound to G4 DNA and fully restored when it is displaced
by the ligand. Different from TO and TO-PRO-3, PhenDV displays a higher affinity towards G4 [47]
(Table 1) and does not interact with duplex DNA. Thus, the displacement assays were carried on
only with G4 sequences. In contrast to TO and TO-PRO-3, the binding constants of PhenDV are
largely spread from 106 M−1 to 6 × 107 M−1 (Table 1). For 21CTA and 22AG, for which PhenDV
displays the same affinity, the dye displacement is very similar for each metal complex. At the opposite,
as PhenDV is much more affine than TO for CEB25-WT (107 M−1 versus 106 M−1) and for c-myc
(6 × 107 M−1 versus 5 × 106 M−1), the dye displacement by the complexes are less efficient, especially
in the case of c-myc. However, as for TO and TO-PRO-3, the same complex ranking has been observed:
Pt-ctpy, Pt-BisQ, and Pt-ttpy are the most affine ligands, and the least affine are Pt-cpym, Pt-tpy, and
Pt(PA)-tpy (Figure 3C and Table S4). In conclusion, FID experiments led to more similar rankings than
the FRET experiments for the evaluated metal complexes on the different tested G4.
Table 1. The PhenDV and TO affinity constants measured in the presence of 22AG, c-myc, 21CTA, and
CEB25-WT G4 structures.
DNA Sequence (5’ to 3’)
PhenDV TO
KA (M−1) Dye:DNA KA (M−1) Dye:DNA
22AG AG3T2AG3T2AG3T2AG3 3 × 106 (a) 2:1 1 × 106 (a) 1:1
c-myc TGAG3TG3TAG3TG3TA2 6 × 107 4:1 5 × 106 (b) 1:1
21CTA AG3CTAG3CTAG3CTAG3 1 × 106 3:1 1 × 106 (b) 1:1
CEB25-WT AG3TG3TG3TG3T 1 × 107 (a) 4:1 1 × 106 (a) 1:1
(a) Determined in Reference [47]. (b) Determined in Reference [48].
2.3. Quadruplex Platination
Previous studies led by Bertrand et al. have shown that the terpyridine platinum complexes
Pt-tpy and Pt-ttpy were also able to react with the human telomeric G4 (22AG) exclusively with
adenines located within the loops whereas Pt-BisQ was not able to metallate 22AG [31]. As well,
Pt-ttpy was found to platinate at the 3’-end exclusively in the proximity of the external G-quartet of
22AG; meanwhile, Pt-tpy metallates the most accessible nucleophilic base of 22AG [35], suggesting no
tetrad interaction. It has been hypothesized that the Pt-ttpy coordination to DNA is, therefore, being
driven by its affinity for the G4 structure, a hypothesis that has been supported by the demonstration
of the stacking of Pt-ttpy on the external quartet of the c-myc derived G4 [42].
The platination reaction of the c-myc oncogene in the presence of our set of candidates (Pt-tpy,
Pt-ttpy, Pt-BisQ, Pt-ctpy, Pt-vpym, and Pt-cpym) bearing a labile ligand was followed by gel
electrophoresis and the binding sites identified by 3’-exonuclease digestion experiments.
The five platinum complexes were incubated for 18 h at 32 ◦C with pre-folded 5’-end 32P
radiolabeled c-myc DNA (10 or 100 µM) and loaded on denaturing polyacrylamide gel electrophoresis
(Figure 4).
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Figure 4. The denaturating gel electrophoresis (15% acrylamide) of platination adducts generated by
(A) Pt-ttpy, (B) Pt-tpy, and (C) Pt-BisQ in the presence of c-myc (10 µM for (A) and (B) and 100 µM
for (C)) in K+100 buffer after 18 h incubation at 32 ◦C. UT is untreated.
Two main accelerated bands (A1 and A2) were detected for Pt-ttpy and three were detected for
Pt-tpy (B1, B2, and B3) in the presence of 10 µM of DNA. However, for Pt-BisQ, two accelerated
bands (C1 and C2) and one retarded band (C3) were only detected at higher DNA concentration
(100 µM). It is noteworthy that c-myc platination products migrate faster that the non-platinated
G4, resulting in a stark contrast if compared to 22AG in which platination products migrate slower
(Figure 2): this is due to the presence of the still folded G4 structures that resist to denaturation,
as already found [42]. Non-defined platination products were detected for Pt-ctpy, Pt-cpym, and
Pt-vpym on gel electrophoresis at 100 µM of DNA (Figure S5), suggesting that the structure unfolds
during platination giving rise to many platinated products. The platination sites of Pt-ttpy, Pt-tpy, and
Pt-BisQ were determined by 3’-exonuclease digestion, which stops at the platinated base, followed by
a de-platination treatment of the digested fragments with NaCN (Figures S6 and S7). The exact length
of the digested de-platinated fragment was deduced from its migration compared with the one of a
digestion ladder of the c-myc sequence on a denaturating gel electrophoresis.
Pt-ttpy forms a platination adduct on the 3’-end of the oligonucleotide, mainly on A21/A22 bases
but also, to a lesser extent, on the inner loop of the quadruplex structure, on A12/G13 bases (Figure 5A).
In addition, the less affine complex Pt-tpy can also form adducts on both flanking sequences of the G4
structure, on T20/A21 at the 3’-end and on G2/A3 on the 5’-end, while the larger aromatic complex
Pt-BisQ forms exclusively a 3’-end adduct on G19/T20 bases with c-myc (Figure 5B).
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2.4. Kinetics and Selectivity Studies
The selectivity of c-myc platination produced by Pt-ttpy and Pt-tpy, the two complexes able
to produce efficient platination products at low G4 concentration, was finally assessed by gel
electrophoresis by employing the same concentrations used for the FRET-melting experiments. The
formation of the platinated products was followed as a function of time (Figures S8 and S9) on two
32P-radiolabeled DNA, c-myc* and ds26*. Pt-ttpy is able to metallate a large amount of G4 DNA
c-myc* within 120 min of incubation (Figure 6).
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Figure 6. The kinetics of the formation of the platination products on 32P radiolabelled c-myc* (0.2 µM)
with (grey square) or without (grey circle) cold duplex competitor DNA ds26 (10 µM) or on 32P
radiolabelled ds26* (10 µM) with (black triangle) or without (black diamond) cold c-myc competitor
(0.2 µM) in the presence of (A) Pt-ttpy or (B) Pt-tpy in a K+10 buffer quantified from the denaturing
acrylamide gel electrophoresis (Figures S8 and S9).
When adding an excess of duplex DNA (ds26) as a competitor, neither the amount of platinated
products nor platination kinetics are affected. In contrast, when c-myc was added as a competitor, the
platination kinetic of ds26* was affected. These results confirm the high selectivity of the platination
reaction performed by Pt-ttpy with G4 DNA structures.
In contrast, the platination of c-myc* by Pt-tpy is more affected by the presence of the duplex
competitor whereas the platination of ds26* is not affected by the addition of c-myc. These results
confirm the low binding selectivity of Pt-tpy for G4. The amount of G4 adducts obtained with Pt-tpy
is higher than with Pt-ttpy, confirming that Pt-tpy can react easily with all the accessible nucleophilic
sites of the structure without previous stacking to the external tetrad. In contrast, the reactivity of
Pt-ttpy is limited to the residues in the vicinity of the external G-quartets which have been shown by
NMR to be its main binding sites [42].
2.5. In Vitro Cytotoxicity
Finally, we evaluated the effect of the complexes on the growth of two ovarian cancer cell lines
A2780 and A2780cis, which are respectively sensitive and resistant to the antitumor drug cisplatin,
and one normal lung cell line CCD19Lu. All cell lines have been treated for 96 h with increasing doses
of complexes. Platinum complexes show cytotoxicity in the µM range (IC50 from 0.08 to 6 µM) as a
function of their structure and can be classified as follows: Pt(PA)-tpy > Pt-vpym > cisplatin > Pt-ttpy
≥ Pt-tpy ≥ Pt-ctpy > Pt-cpym > Pt-BisQ (Table 2). Moreover, none of the platinum complexes show a
significant cross-resistance to cisplatin since no significant differences between cisplatin-sensitive and
resistant cell lines could be highlighted (IC50ratio A2780cis/A2780 < 1.6). However, all of them show
no specificity for cancer cell lines, similar to the clinical anticancer drug cisplatin.
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Table 2. The IC50 (µM) of the various platinum complexes calculated from the proliferation of
A2780, A2780cis, and CCD19Lu cell lines after 96 h treatments and their resistance factor (IC50ratio
A2780cis/A2780).
A2780 A2780 cis Resistance Factor CCD19Lu
Pt-BisQ 4.00 6.00 1.5 4.10
Pt-ctpy 4.60 5.00 1.1 5.20
Pt-ttpy 2.50 2.50 1.0 1.75
Pt-cpym 3.80 5.00 1.3 1.80
Pt-vpym 0.70 0.40 0.6 0.70
Pt-tpy 3.00 5.00 1.6 3.00
Pt(PA)-tpy 0.08 0.05 0.6 0.12
cisplatin 0.33 3.00 9.1 0.20
3. Discussion
In this study, we explored the chemical space around the terpyridine aromatic core to put
in evidence the key elements that drive affinity and selectivity for various G4-DNA exhibiting
polymorphic (22AG), antiparallel (21CTA), long looped parallel (CEB25-WT), and short looped parallel
(c-myc) topologies. The FRET-melting assays pointed out three ligands exhibiting higher binding
inducing stabilization independently from the G4 topology (Figure 1A), namely Pt-BisQ, Pt-ctpy,
and Pt-ttpy (∆Tm > 10 ◦C). Whereas Pt-vpym, Pt-cpym, and Pt-tpy showed less stabilizing capacities
(∆Tm < 10 ◦C), and no stabilization was observed for Pt(PA)-tpy. However, their selectivity for G4 over
duplex DNA is moderate since their ∆Tm decreases significantly in the presence of competitor duplex
DNA (Figure 1B–E). This trend was then confirmed by FID assays. Interestingly, PhenDV was a better
probe than TO-PRO-3 and TO able to discriminate the relative affinity of the complexes for each G4
topology. Indeed PhenDV, which displays higher binding constants for all of the evaluated G4s, was
shown to discriminate more significantly among high affinity G4 ligands [47]. None of the complexes
was able to displace PhenDV from c-myc in contrast to TO and TO-PRO-3, the exception represented
by the benchmark l ligand, PhenDC3. This is consistent with the particularly high affinity of PhenDV
for the c-myc structure (Table 1) which induces a harsh competition as compared to the other markers,
thereby leading to the selection of only very high affinity ligands (e.g., PhenDC3). Alternatively, other
binding sites cannot be excluded for the platinum complexes in the presence of PhenDV.
It is quite surprising that the relative binding properties of the complexes determined from
FRET-melting and FID experiments are consistent despite the formation of non-negligible amounts
of platinum adducts (up to 50%) during the FRET-meting experiments (Figure 2). This suggests
that the platination of the bases already accessible within the loops or released from the G-quartets
during the thermal denaturation conditions does not shift significantly the equilibrium towards the
unfolded state in FRET conditions. Nevertheless, it could explain the lower ∆Tm observed on c-myc
versus 22AG independently from the metal complex since the amount of platination products is more
important for c-myc than 22AG in these conditions. Of note, these FRET-melting experiments, done in
thermal-denaturing conditions, lead to an irreversible process. Indeed, the N7 platination of guanines
would prevent the formation of the G-quartets and consequently the folding in G4 [52] in thermal
renaturation conditions.
Altogether the data highlight the need of different and complementary methods for the
determination of the relative affinity of ligands for G4.
Considering the structure–activity relationship, our data show that the extension of the aromatic
core modifies the affinity of the complexes for the G4-DNA structures. Since Pt(PA)-tpy did not show
any affinity for G4, it can be claimed that introducing a phenylacetylene group on the platinum may
support a decrease in affinity for the G4. While extending the terpyridine by a tolyl (Pt-ttpy), a tolyl
with a protonable side chain (Pt-ctpy), or replacing the terpyridine core by a bisquinoline (Pt-BisQ)
increase the affinity of all the complexes for G4-DNA, modifying the terpyridine core (Pt-vpym and
Pt-cpym) reduces the affinity for G4. Interestingly, Pt-ttpy showed a high affinity for 22AG. This could
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be related to the recent results showing that one of the cellular targets of Pt-ttpy is indeed telomeric
DNA [37,39,44]. Noteworthily, while the selectivity of the present complexes for G4 over duplex DNA
is moderate in vitro (Figure 2B–E), the example of Pt-ttpy indicates that low selective ligands can reach
their cellular target even in the presence of genomic DNA.
One expected property of these complexes is to form mono-adducts with DNA. Our in vitro data
show that the relative platination of c-myc G4 over duplex DNA by Pt-ttpy and Pt-tpy is correlated
to the relative affinity for both structures, suggesting that the platination events are driven by the
recognition of the DNA structures. However, the relative affinity of present complexes for G4 is not
correlated to their platination efficiency. In this regard, Pt-BisQ, one of the most relevant complexes, is
less susceptible to induce platination of c-myc G4 in vitro if compared to Pt-ttpy, Pt-ctpy, and Pt-tpy
and does not show any alkylation on 22AG G4 [31]. This behavior can be explained by i) slow exchange
kinetics of the chloride, mandatory for the direct coordination of Pt(II) to the nucleophilic site [53], and
ii) the effect produced by the extension of the terpyridine core that can mask the nucleophilic sites of
the G4 and/or the accessibility of Pt(II) [42]: indeed, the platinated bases depend on the nature of the
complexes (A12, G13, A21, and A22) for Pt-ttpy and G19 for Pt-BisQ.
Finally and importantly, the IC50 of the complexes are in the µM range, except for Pt(PA)-tpy
which is active at nM concentration in A2780 cell lines. However, all the complexes overcome the
cisplatin resistance in A2780cis cell lines, providing new interesting anticancer drug candidates. This
suggests that they may enter cells via a pathway independent from the copper carrier proteins used by
cisplatin [54]. Among them, Pt(PA)-tpy is the most efficient complex despite its inability to form DNA
adducts. Therefore, our results pointed out that the cellular efficiency of a panel of platinum complexes
is not strictly related to their affinity for the various G4-DNA structures or their capacity to platinate
in vitro DNA structures. Many other factors, in addition to their cellular target, must be taken into
account, such as their cellular uptake and their binding to genomic DNA, as already shown for other
platinum complexes [33,55]. For example, previous studies showed that the genomic DNA binding of
Pt-tpy and Pt-ttpy is less efficient than the one of cisplatin, as compare to their cellular uptake.
In conclusion, the modulation of the terpyridine core of platinum complexes may greatly influence
their in vitro affinity for G4 and their capacity to induce specific metallation of G4 in vitro and may
be promising as future anticancer drugs overcoming the resistance to cisplatin. The identification of
the cellular targets, which is ongoing, could definitely indicate if they also represent potential drugs
targeting G4 in cellulo.
4. Materials and Methods
4.1. Materials
Oligonucleotides purified by reversed-phase HPLC were purchased from Eurogentec (Angers,
France). The dual fluorescently labeled oligonucleotides were purchased from Eurogentec.
The donor fluorophore was 6-carboxyfluorescein (FAM) and the acceptor fluorophore was
6-carboxytetramethylrhodamine (TAMRA).
PhenDV was synthesized as already described [47].
Stock solutions of the ligands (2 mM in DMSO) were used for G4-FID, FRET-melting assay, and
fluorimetric titration, unless otherwise stated, and were stored at−20 ◦C. TO, TO-PRO-3, and cacodylic
acid were purchased from Aldrich and used without further purification. Stock solutions of TO (2 mM
in DMSO), PhenDV (2 mM in DMSO), and TO-PRO-3 (1 mM in DMSO) were used for the G4-FID
assay. Fluorescent probe powders and solutions were stored and used, protected from light, and used
as aliquots to avoid freeze–thaw cycles.
The FRET-melting measurements are performed on a 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) with a Microamp Fast optical 96-well reaction plate
(Applied Biosystems). HT-G4-FID measurements were performed on a FLUOstar Omega microplate
reader (BMG Labtech, Champigny-sur-Marne, France) with 96-well Non-Binding Surface black
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with black bottom polystyrene microplates (Corning). Fluorescence measurements (i.e., fluorimetric
titration) were performed on a Cary Eclipse Fluorescence spectrophotometer (Agilent Technologies,
Les Ulis, France).
4.2. Organic Synthesis
1H and 13C spectra were recorded at 300 MHz and 75 MHz on a Bruker Avance 300 spectrometer
and at 500 MHz and 126 MHz on a bruker Avance 500 spectrometer (at the NMR service of ICSN)
using TMS as the internal standard (Figure S1). DMSO-d6 and CDCl3 were purchased from SDS.
Proton chemical shifts are reported in ppm (δ) with the solvent reference as the internal standard
(DMSO-d6, δ 2.50 ppm; CDCl3, δ 7.26 ppm). Data are reported as follows: chemical shift (multiplicity
(singlet (s), doublet (d), triplet (t), and multiplet (m)), coupling constants (Hz), and integration). LC-MS
spectra (ESI in the positive ion mode) were performed with a Waters ZQ instrument (source voltage
50–75 kV). High resolution mass spectrometry (HR-MS) was performed at the Small Molecule Mass
Spectrometry platform of IMAGIF (Centre de Recherche de Gif, Gif-sur-Yvette, France). Analytical
thin-layer chromatography (TLC) was performed using silica gel 60 Å UV254 precoated plates (0.20 mm
thickness) from Macherey Nagel (Hoerdt, France). Visualization was accomplished by irradiation
with a UV lamp. Preparative flash chromatography was carried on a CombiFlash Companion) from
Teledyne Isco(Lincoln, NE, USA) equipped with packed silica cartridges from Interchim (Montluçon,
France). Starting materials were purchased from Sigma-Aldrich (Lyon, France), Alfa Aesar (Karlsruhe,
Germany), and Acros (Geel, Belgium). The 2,4-dichloro-6-(4-methoxyphenyl)pyrimidine (CAS
[154499-86-2]) [49], vpym (CAS [1297529-36-2]) [50] were prepared as described in the literature.
4-(4-Methoxyphenyl)-2,6-bis(pyridin-2-yl)pyrimidine (1). 1H-NMR (300 MHz, CDCl3): δ (ppm) 8.91 (d, J =
3.0 Hz, 1H), 8.76 (m, 4H), 8.39 (d, J = 9.0 Hz, 2H), 7.92 (m, 2H), 7.58–7.38 (t, J = 8.0 Hz, 2H), and 7.06 (d,
J = 9.0 Hz, 2H), 3.91 (s, 3H); 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 165.2, 163.9, 163.6, 162.1, 155.6,
154.4, 150.1, 149.4, 137.1, 136.8, 129.5, 129.2, 125.6, 124.6, 124.1, 122.4, 114.2, 111.1, and 55.4; and LR-MS
(ESI-MS) m/z = 341.13 [M + H]+.
In a dry round-bottomed flask, 2,4-dichloro-6-(4-methoxyphenyl)pyrimidine (677 mg, 2.65 mmol,
1.0 eq) and Pd(Ph3)4 (460 mg, 0,39 mmol, 0.15 eq) are introduced under argon atmosphere. Dry
toluene (20 mL) is added, and a cooling system is installed. The mixture is degassed for 10 min
before the addition of 2-(tributylstannyl)pyridine (2.1 mL, 6.63 mmol, 2.5 eq) and heated at reflux
(110 ◦C) for 15 h. Then, 30 mL of water is added. The crude mixture is filtrated on a pad of celite
and washed with ethyl acetate, followed by extraction. The combined organic phase is dried over
MgSO4, filtered and concentrated to dryness. The product is purified by column chromatography
(Al2O3—cyclohexane/AcOEt 50/50) to afford the expected product (749 mg, 83%).
4-(2,6-Bis(pyridin-2-yl)pyrimidin-4-yl)phenol (2). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 10.15 (s, 1H),
8.84 (s, 2H), 8.74 (s, 1H), 8.65 (t, J = 7.5 Hz, 2H), 8.29 (d, J = 7.0 Hz, 2H), 8.07 (dt, J = 14.0, 7.0 Hz, 2H),
7.76–7.51 (m, 2H), and 6.99 (d, J = 9.0 Hz, 2H); 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 165.3, 163.0,
161.6, 156.2, 151.8, 149.5, 147.5, 146.9, 143.4, 138.6, 129.9, 128.9, 126.9, 126.1, 125.7, 122.8, 116.1, and
111.9; and LR-MS (ESI-MS) m/z = 327.31 [M + H]+.
Compound (1) (200 mg, 0.58 mmol, 1.0 eq) is dissolved in anhydrous CH2Cl2 (10 mL) under argon
atmosphere. The mixture is cooled down to −78 ◦C, and BBr3 (200 µL, 2.11 mmol, 3.6 eq) is added
dropwise. After cooling back to room temperature, the mixture is stirred for one night and quenched
by ice addition. The red solid is filtered, washed, and crystallized in methanol (96 mg, 50%).
2,4-Di(pyridin-2-yl)-6-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrimidine (cpym). 1H-NMR (300 MHz, CDCl3):
δ (ppm) 8.86 (m, 1H), 8.71 (m, 4H), 8.32 (d, J = 9.0 Hz, 2H), 7.85 (m, 2H), 7.37 (m, 2H), 7.02 (d, J = 9.0 Hz,
2H), 4.15 (t, J = 6.0 Hz, 2H), 2.89 (t, J = 6.0 Hz, 2H), 2.60 (m, 4H), and 1.77 (m, 4H); 13C-NMR (75 MHz,
CDCl3): δ (ppm) 165.3, 164.0, 163.7, 161.5, 155.7, 154.5, 150.1, 149.5, 137.3, 137.0, 129.6, 129.3, 125.5,
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124.8, 124.2, 122.5, 114.9, 111.3, 77.6, 77.2, 76.7, 67.3, 55.1, 54.9, and 23.6; LR-MS (ESI-MS) m/z = 424 [M
+ H]+; HR-MS (ESI+) m/z = 424.2137; and found, 424.2125.
In a round-bottomed flask under argon atmosphere, 4-(2,6-bis(pyridin-2-yl)pyrimidin-4-yl)phenol
(50 mg, 0.15 mmol, 1.0 eq), N-(2-chloroethyl)pyrrolidine hydrochloride (26 mg, 0.15 mmol, 1.0 eq), and
cesium carbonate (149 mg, 0.46 mmol, 3 eq) are introduced with DMF (2 mL). The mixture is stirred
overnight at 100 ◦C. The solvent is removed under vacuum. Ethyl acetate (20 mL) and water (20 mL)
are added for extraction. The combined organic phase is dried over MgSO4, filtered, and concentrated
to dryness to afford the compound cpym (58 mg, 89%).
Chloro-(2,4-di(pyridin-2-yl)-6-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrimidine)-platinum(II) Chloride
(Pt-cpym). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 9.25 (s, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.75
(dd, J = 10.0, 5.5 Hz, 2H), 8.67–8.40 (m, 5H), 7.96 (dd, J = 12, 5.5 Hz, 2H), 7.16 (d, J = 9.0 Hz, 2H),
4.31 (t, J = 4.5 Hz, 2H), 3.02 (s, 2H), 2.74 (m, 4H), and 1.78 (m, 4H); 13C-NMR (126 MHz, DMSO-d6):
δ 166.2, 163.4, 161.8, 159.5, 156.5, 154.6, 151.8, 151.5, 143.0, 142.7, 131.0, 130.94, 130.7, 127.7, 127.2,
126.5, 115.5, 113.1, 54.1, 53.8, 29.2, and 23.1; LR-MS (ESI-MS) m/z = 654 [M + H]+; HR-MS (ESI+):
m/z = 653.1395 calculated for C26H25N5OClPt; and found, 653.1367.
In a round-bottomed flask under argon atmosphere, cpym (40 mg, 0.09 mmol, 1.0 eq) is dissolved
in a minimal amount of CH2Cl2 (3 mL). Platinum catalyst Pt(DMSO)2Cl2 (40 mg, 0.09 mmol, 1.0 eq)
is introduced dropwise with methanol (3 mL). The mixture is stirred at 50 ◦C for 20 h. The crude
product is filtered on membrane, washed with a mixture of MeOH/CH2Cl2/acetone, and dried by
Et2O. Pt-cpym is obtained as a dark powder (20 mg, 31%).
Chloro-(E)-4-(2-(2,6-di(pyridin-2-yl)pyrimidin-4-yl)vinyl)-N,N-dimethylaniline-platinum(II) Chloride
(Pt-vpym). 1H-NMR (500 MHz, DMSO-d6): δ 8.93 (d, J = 5.0 Hz, 1H), 8.90 (d, J = 5.0 Hz, 1H),
8.65 (d, J = 7.5 Hz, 1H), 8.60–8.50 (m, 3H), 8.48 (d, J = 7.5 Hz, 1H), 8.24 (d, J = 15.5 Hz, 1H), 8.05–7.99 (m,
2H), 7.58 (d, J = 9.0 Hz, 2H), 7.05 (d, J = 15.5 Hz, 1H), 6.72 (d, J = 9.0 Hz, 2H), and 3.04 (s, 6H);13C-NMR
(126 MHz, DMSO-d6): δ 166.6, 161.6, 157.9, 156.8, 155.2, 152.5, 151.8, 151.6, 144.8, 142.8, 142.5,
131.1, 130.7, 130.3, 126.7, 126.6, 122.0, 118.4, 114.2, 112.1, and 45.7; LR-MS (ESI-MS) calculated for
[C24H21N5ClPt]+, m/z = 610.22 [M + H]+; HR-MS (ESI+): m/z = 609.1133; and found, 609.1140.
In a dry round-bottomed flask under argon atmosphere, vpym (50 mg, 0.13 mmol, 1.0 eq) is
dissolved in the minimal amount of CH2Cl2 (3 mL). Platinum catalyst Pt(DMSO)2Cl2 (55.9 mg,
0.13 mmol, 1.0 eq) is introduced dropwise with methanol (3 mL). The dark reaction mixture is stirred
overnight at room temperature. The crude product is filtrated on nylon membrane, washed with a
mixture of MeOH/CH2Cl2/acetone, and dried by Et2O. Pt-vpym is obtained as a dark purple solid
(54 mg, 74%).
Phenylethylny-(2,6-bis(pyridin-2-yl)pyridine)-platinum(II) Hexafluorophosphate (Pt(PA)-tpy). 1H-NMR (300
MHz, DMSO-d6): δ 9.05 (d, J = 4.8 Hz, 1H), 8.77–8.31 (m, 6H), 8.01–7.73 (m, 2H), 7.48 (d, J = 7.1 Hz,
2H), and 7.44–7.08 (m, 5H); and LR-MS (ESI+): m/z = 529.9 [M + H]+.
Pt-tpy (100 mg, 0.216 mmol), phenylacetylene (47.5 µL, 0.431 mmol), copper iodide (4.11 mg,
0.022 mmol), and triethylamine (30.0 µL, 0.216 mmol) were dissolved in DMF (10 mL) to give a bright
red suspension. The reaction was stirred with a magnetic stir bar at room temperature under argon
for 3 days. The solution slowly turned dark green. An aqueous saturated solution of NH4PF6 was
added. The dark green precipitate was filtered and washed with water and plenty of diethyl ether
(yellow filtrate) until the filtrate turned black and was finally dried to afford a green powder (42.3 mg,
0.080 mmol, 37.1% yield).
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4.3. Oligonucleotides
For FI, fluorimetric, and gel electrophoresis experiments,
22AG 5’-A GGGTTAGGGTTAGGGTTAGGG-3’
c-myc (myc22) 5’-TGAGGGTGGGTAGGGTGGGTAA-3’
ds26 5’-CAATCGGATCGAATTCGATCCGATTG-3’
21CTA AGGGCTAGGGCTAGGGCTAGGG
CEB25-WT AAGGGTGGGTGTAAGTGTGGGTGGGT
For FRET experiments,
F-21-T 5’-FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA-3’
F-myc-T 5’-FAM-TGA GGG T GGG TA GGG T GGG TAA-TAMRA-3’
F-21CTA-T 5’-FAM-AGGGCTAGGGCTAGGGCTAGGG- TAMRA-3’
F-CEB25-WT-T 5’-FAM-AGGGTGGGTGTAAGTGTGGGTGGGT- TAMRA-3’
4.4. Preparation of Oligonucleotides
For the G4-FID assay, the oligonucleotides were dissolved in K+100 buffer (10 mM lithium
cacodylate buffer pH 7.3, 100 mM KCl, 1% DMSO). Oligonucleotide concentrations were determined
on the basis of their absorbance at 260 nm. For the fluorimetric titration, the oligonucleotides were
dissolved in K+100 buffer without DMSO. For the FRET-melting assay, the oligonucleotides were
dissolved in K+1 buffer (10 mM lithium cacodylate buffer pH 7.3, 1 mM KCl, 99 mM LiCl) except for
F-21-T. F-21-T was dissolved in K+10 buffer (10 mM lithium cacodylate buffer pH 7.3, 10 mM KCl,
90 mM LiCl).
Prior to use, all oligonucleotides were pretreated by heating at 95 ◦C for 5 min, then rapidly cooled
to 4 ◦C to favor the intramolecular folding by kinetic trapping. Duplex-DNA ds26 was prepared by
heating the self-complementary strand at 90 ◦C for 5 min in K+1 buffer followed by a slow cooling
over 6 h.
4.5. FRET-Melting Experiments
The stabilization of the compounds with a quadruplex-structure was monitored via FRET-melting
assay performed in 96-well plates on a real-time PCR apparatus 7900HT Fast Real-Time PCR
System as follows: 5 min at 25 ◦C and then an increase of 0.5 ◦C every minute until 95 ◦C. Each
experimental condition was tested and replicated in a volume of 25 µL for each sample. The
FRET-melting assay was performed with three dual fluorescently labeled DNA oligonucleotide
sequences oligonucleotides. The donor fluorophore was 6-carboxyfluorescein, FAM, and the acceptor
fluorophore was 6-carboxytetramethylrhodamine, TAMRA. The 96-well plates (Applied Biosystems)
were prepared by aliquoting the annealed DNA (0.2 µM in K+1 or K+10 buffer) into each well, followed
by 1 µL of the ligand (100 µM (5 eq) in DMSO). For competition experiments, duplex competitors
were added to 200 nM quadruplex sequences at final concentrations of 3.0 µM (15 eq) and 10.0 µM
(50 eq), with a total reaction volume of 25 µL, with the labeled oligonucleotide (0.2 µM) and the ligand
(1 µM). Measurements were made with excitation at 492 nm and detection at 516 nm. The change
in the melting temperature at 1.0 µm compound concentration, ∆Tm (1.0 µM), was calculated from
at least two experiments by subtraction of the blank from the averaged melting temperature of each
compound (1.0 µM). The final analysis of the data was carried out using Origin Pro 8.6 data analysis.
4.6. HT-G4-FID Assay
Each G4-FID assay was performed in a 96-well Non-Binding Surface black with black bottom
polystyrene microplates (Corning). Every ligand was tested on a line of the microplate, in duplicate.
The microplate was filled with (a) K+100 solution (qs for 200 µL), (b) 10 µL of a solution of
pre-folded oligonucleotides (5 µM) and fluorescent probe (TO/TO-PRO-3 (10 µM—2 eq) or PhenDV
(7.5 µM—1.5 eq)), and (c) an extemporaneously prepared 5 µM ligand solution in K+100 buffer (0 to
100 µL) along the line of the microplate, i.e., from column A to column H: 0, 0.125, 0.25, 0.375, 0.5,
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0.625, 0.75, 1.0, 1.25, 1.5, 2.0, and 2.5 µM. After 5 min of orbital shaking at 500 rpm, fluorescence is
measured using the following experimental parameters: positioning delay of 0.5 s, 20 flashes per well,
emission/excitation filters for TO at 485/520, TO-PRO-3 at 620/670, and PhenDV at 355/520 gain
adjusted at 80% of the fluorescence from the most fluorescent well (i.e., a well from column A for TO
and a well from column H).
The percentage of TO displacement is calculated from the fluorescence intensity (F), using
% TO displacement = 1− F
F0
(1)
where F0 is the fluorescence from the fluorescent probe bound to DNA without added ligand.
In the case of PhenDV, the fluorescence of the unbound probe is not negligible. The percentage of
displacement becomes
% PhenDV Displacement =
F− F0
Fligand+probe − F0 (2)
The PhenDV displacement is calculated from the fluorescence intensity F; F(ligand+probe), which
refers to the fluorescence of the probe in presence of the ligand (without G4); and F0, which is the
fluorescence without added ligand. The term F(ligand+probe) is necessary as the ligand can quench
the fluorescence of the probe. The percentage of displacement is then plotted as a function of the
concentration of the added ligand. The DNA affinity was evaluated by the concentration of ligand
required to decrease the fluorescence of the probe by 50%, was noted DC50, and was determined after
non-linear fitting of the displacement curve.
4.7. Fluorimetric Titrations for Affinity Constant Evaluation Reported in Table 1
A temperature of 20 ◦C was kept constant with a thermostated cell holder. Each titration was
performed in a 1 mL quartz cell in K+100-buffer in a total volume of 1 mL. Titrations were performed
with a solution of the fluorescent probe (TO; 0.5 µM or PhenDV; 1 µM) in the corresponding buffer
in which gradual addition of oligonucleotides was carried out (up to 10 molar equivalents). After
each addition, a fluorescence emission spectrum was recorded at 501 or 387 nm excitation wavelength,
respectively. The fluorescence emission area was measured between 510–750 or 397–700 nm,
respectively, with 1.0 nm increments, a 0.1 s integration time, and 3/3 nm (excitation/emission) slits.
The titration curves were obtained by plotting the fluorescence emission area enhancement against
the oligonucleotide concentration. Fluorimetric titrations were performed according to published
procedures [56], and the binding constants were determined by fitting of the experimental data to the
theoretical model:
I
I0
= 1 +
Q− 1
2
(
A + xn + 1−
√
(A + xn + 1)2 − 4xn
)
(3)
where Q = I∞/I0 is the minimal fluorescence intensity in the presence of excess ligand; n is the number
of independent binding sites per quadruplex; A = 1/(Kb × cL); and x = cG4/cL is the titration variable.
4.8. Gel Electrophoresis
The oligonucleotides were 5’-end-labelled using a polynucleotide kinase and (γ32P)-ATP (Perkin
Helmer). The reaction products were purified by electrophoresis on 20% denaturing gel. Sample
platinations were prepared by folding a mixture of 5’-end-radiolabeled DNA and 10 µM or 100 µM
of non-radiolabeled material in 100 mM KClO4 or 100 mM KCl solution except for the platination
reaction in the denaturing temperature conditions. The folding was achieved by heating the samples
at 90 ◦C for 5 min, followed by slow cooling to room temperature over the course of 2 h to induce
the formation of the quadruplex structure. It was then incubated with platinum complexes, and
platinated products were separated by electrophoresis on 15% denaturing gel. They were then eluted
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from gel, precipitated, treated by 3’-exonuclease at 37 ◦C for 30 min, and loaded on a 20% denaturing
gel. The digested fragments were eluted from this gel precipitated, treated over night by NaCN 0.2M,
precipitated, and loaded once again on a 20% denaturing gel. Gels were scanned using a STORM860
(Molecular Dynamics).
4.9. Cell Culture
The ovarian carcinoma cell lines and human normal lung cells were purchased from ATCC and
were grown in complete RPMI medium (ovarian) and DMEM (human lung cells) supplemented with
10% fetal calf serum, in the presence of penicillin, streptomycin. The resistance of A2780cis cells to
cisplatin was maintained by monthly treatment with 1 µM cisplatin for 4 days. Concentrated stock
solutions of complexes were conserved at −20 ◦C (DMSO/Water) and freshly diluted in water just
before the experiments. Cells were treated with various concentrations of platinum complexes at 37 ◦C
under humidity and 5% CO2 conditions for 96 h. Cellular growth was quantified using the particle
counter MOXI (VWR).
Supplementary Materials: The supplementary materials are available online.
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